Today’s Stocks: JPMorgan Chase & Co. (NYSE:JPM), ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC), Midcoast Energy Partners, L.P. (NYSE:MEP), Immune Design Corp. (NASDAQ:IMDZ), IsoRay (NYSEMKT:ISR)

JPMorgan Chase & Co. (NYSE:JPM) belongs to Financial sector. Its net profit margin is 40.20% and weekly performance is 1.13%. On last trading day company shares ended up $68.09. JPMorgan Chase & Co. (NYSE:JPM) distance from 50-day simple moving average (SMA50) is 2.60%. JPMorgan Chase & Co. (NYSE:JPM) said that, it is projected to report second-quarter earnings of $1.44 a share.

ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) shares moved down -0.90% in last trading session and ended the day at $0.48. IMUC return on assets is -26.50%. ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) quarterly performance is -1.33%. ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) provides an overview of the ImmunoCellular Therapeutics, Ltd.’s pharmaceutical research and development focus.

On 13 July, Midcoast Energy Partners, L.P. (NYSE:MEP) shares moved up 0.87% and was closed at $10.41. Midcoast Energy Partners, L.P. (NYSE:MEP) year to date (YTD) performance is -19.81%. Midcoast Energy Partners, L.P. (NYSE:MEP) said that, it will host a webcast conference call to discuss its 2015 second quarter financial results on 30 July.

Immune Design Corp. (NASDAQ:IMDZ) shares moved up 0.54% in last trading session and ended the day at $24.17. IMDZ Gross Margin is 91.60% and its return on assets is -56.80%. Immune Design Corp. (NASDAQ:IMDZ) quarterly performance is -1.79%. Zacks upgraded shares of Immune Design Corp. (NASDAQ:IMDZ) from a hold rating to a buy rating in a research note released on Tuesday morning. They currently have $24.00 target price on the stock.

IsoRay, Inc. (NYSEMKT:ISR) shares moved down -2.82% in last trading session and ended the day at $1.38. ISR Gross Margin is -4.80% and its return on assets is -17.60%. IsoRay, Inc. (NYSEMKT:ISR) quarterly performance is -7.38%.On 29 June, IsoRay, Inc. (NYSEMKT:ISR) announced that Dr. Brian J. Moran, Director of Chicago Prostate Cancer Center in Westmont, Illinois, has initiated a study of focal prostate cancer treatment using Cesium-131 brachytherapy.

Leave a Reply

Your email address will not be published. Required fields are marked *